Andres Forero - Concepedia

Author

Andres Forero

University of Alabama at Birmingham ORCID

Also Known As

A FORERO, A Forero, A. Forero, ANDRES FORERO, Alex Forero, Amos, Keith D., Andres Felipe Forero, Andres Forero, Andrés Camilo Prieto Forero, Blackwell, Kimberly

263

Publications

10.8K

Citations

H-Index

Concepts

All Affiliations

University of Alabama at Birmingham Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Washington University in St. Louis Dana-Farber Cancer Institute

About

Andres Forero is an author at University of Alabama at Birmingham specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	4.3K
2	Health Sciences	12	13	2.7K
3	Nursing	4	4	2K
4	Public Health	1	1	10
5	Biostatistics	1	1	10

Andres Forero

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network NursingSurgical OncologyBreast OncologyCancer ScreeningMedicine	2018	1.6K
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, New England Journal of Medicine	2018	1.1K
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff, Clinical Cancer Research	2013	700
NCCN Guidelines Insights: Breast Cancer, Version 1.2017 William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network Preclinical TherapeuticsEndocrine OncologyRadiation MedicineSurgical OncologyBreast Oncology	2017	538
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg, JAMA Oncology	2019	413
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer X. Cynthia, Feng Gao, Jingqin Luo, Clinical Cancer Research	2017	359
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network Surgical OncologyBreast OncologyHealth SciencesMedicineCancer Management	2016	315
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Journal of Clinical Oncology	2013	271
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer Jennifer F. De Los Santos, Alan Cantor, Keith D. Amos, Cancer	2013	198
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Nancy L. Bartlett, Anas Younes, Matthew Carabasi, Blood	2007	196

Page 1